Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer
2022; Elsevier BV; Volume: 167; Issue: 2 Linguagem: Inglês
10.1016/j.ygyno.2022.09.004
ISSN1095-6859
AutoresJune Y. Hou, Jocelyn Chapman, Ekaterina Kalashnikova, William E. Pierson, Karen Smith‐McCune, Geovanni Pineda, Reena M. Vattakalam, Alexandra Ross, Meredith Mills, Carlos J. Suarez, Tracy C. Davis, Robert P. Edwards, M.M. Boisen, Sarah Sawyer, Hsin-Ta Wu, Scott Dashner, Vasily N. Aushev, Giby V. George, Meenakshi Malhotra, Bernhard Zimmermann, Himanshu Sethi, Adam C. ElNaggar, Alexey Aleshin, James M. Ford,
Tópico(s)PARP inhibition in cancer therapy
ResumoEpithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. We examined the utility of circulating tumor DNA (ctDNA) as a prognostic biomarker for EOC by assessing its relationship with patient outcome and CA-125, pre-surgically and during post-treatment surveillance.
Referência(s)